Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Tokyo - Delayed Quote JPY

Nxera Pharma Co., Ltd. (4565.T)

Compare
840.00
-5.00
(-0.59%)
At close: February 21 at 3:30:00 PM GMT+9
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,340,000
12,766,000
15,569,000
17,712,000
8,842,000
Cost of Revenue
6,369,000
3,102,000
926,000
933,000
761,000
Gross Profit
16,971,000
9,664,000
14,643,000
16,779,000
8,081,000
Operating Expense
25,983,000
19,190,000
11,207,000
13,004,000
7,153,000
Operating Income
-9,012,000
-9,526,000
3,436,000
3,775,000
928,000
Net Non Operating Interest Income Expense
-1,066,000
-1,154,000
-93,000
-3,598,000
1,050,000
Pretax Income
-10,078,000
-10,680,000
1,078,000
433,000
1,622,000
Tax Provision
-242,000
-3,487,000
696,000
-584,000
143,000
Net Income Common Stockholders
-9,836,000
-7,193,000
382,000
1,017,000
1,479,000
Diluted NI Available to Com Stockholders
-9,836,000
-7,193,000
382,000
1,017,000
1,479,000
Basic EPS
-114.56
-87.18
4.68
12.53
18.77
Diluted EPS
-114.56
-87.18
4.63
12.40
18.59
Basic Average Shares
86,285.31
82,516.51
81,785.01
81,187.31
78,795.95
Diluted Average Shares
86,285.31
82,516.51
82,590.44
82,590.44
79,558.90
Total Operating Income as Reported
-9,012,000
-9,526,000
3,436,000
3,775,000
928,000
Total Expenses
32,352,000
22,292,000
12,133,000
13,937,000
7,914,000
Net Income from Continuing & Discontinued Operation
-9,836,000
-7,193,000
382,000
1,017,000
1,479,000
Normalized Income
-9,836,000
-7,193,000
1,792,048
874,077.20
1,479,000
Interest Income
1,437,000
1,341,000
663,000
199,000
1,628,000
Interest Expense
2,503,000
2,495,000
756,000
3,797,000
578,000
Net Interest Income
-1,066,000
-1,154,000
-93,000
-3,598,000
1,050,000
EBIT
-7,575,000
-8,185,000
1,834,000
4,230,000
2,200,000
EBITDA
-3,811,000
-5,707,000
3,179,000
5,508,000
3,550,000
Reconciled Cost of Revenue
6,369,000
3,102,000
926,000
933,000
761,000
Reconciled Depreciation
3,764,000
2,478,000
1,345,000
1,278,000
1,350,000
Net Income from Continuing Operation Net Minority Interest
-9,836,000
-7,193,000
382,000
1,017,000
1,479,000
Total Unusual Items Excluding Goodwill
--
--
-1,836,000
206,000
--
Total Unusual Items
--
--
-1,836,000
206,000
--
Normalized EBITDA
-3,811,000
-5,707,000
5,015,000
5,302,000
3,550,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
-425,952
63,077.20
--
12/31/2020 - 7/29/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4587.T PeptiDream Inc.
2,116.00
+1.15%
 
SRZN Surrozen, Inc.
11.51
+2.75%
 
IRON Disc Medicine, Inc.
53.87
-1.21%
 
RYTM Rhythm Pharmaceuticals, Inc.
55.09
-1.75%
 
FYB.DE Formycon AG
27.70
-6.73%
 
CGEM Cullinan Therapeutics, Inc.
8.77
-2.88%
 
ALVR AlloVir, Inc.
10.20
+8.86%
 
OABI OmniAb, Inc.
3.7800
+3.56%
 
ARGX.BR argenx SE
610.80
-1.36%
 
PVLA Palvella Therapeutics, Inc.
19.60
+1.98%